Here, we will report an <i>EGFR</i>-mutated lung adenocarcinoma patient with heterogeneity of resistant mechanisms including <i>EGFR</i> amplification, large fragment deletion of <i>RB1</i>, and histological transformations after targeted treatments. The gene discussed is EGFR; the disease is lung adenocarcinoma.